1849. Tigecycline Susceptibility Trends Among Pathogens Isolated from Complicated Skin and Soft Tissue Infections in North and Latin America: 2011-2015
Background: The
Tigecycline Evaluation Surveillance Trial (TEST) monitors the activity of
tigecycline and other antimicrobials against clinically-relevant pathogens
collected globally. This study reports the activity of tigecycline (TGC) for
gram-positive and –negative isolates collected in North and Latin America from
patients with complicated skin and soft tissue infections (CSSTI).
Methods: There were 378 cumulative sites from North America (NA) and 133
cumulative sites from Latin America (LA) between 2011 and 2015. Non-duplicate
clinical gram-positive and -negative isolates from medical centers in NA and LA
were collected from various skin and skin structure sources during 2011-2015.
Organism identification and antibiotic susceptibility (S) testing was performed
by the local laboratories. Susceptibility testing was performed using broth
microdilution according to CLSI guidelines and categorical interpretation of
results was done using CLSI or FDA breakpoint criteria where appropriate.
Cefoxitin disk testing was performed for all S. aureus to determine
methicillin susceptibility MRSA and MSSA.
Results: The table
provides MIC90 and %S data for TGC against CSSTI isolates
Region %S /MIC90
North America
Latin America
Organism
n
%S
MIC90
n
%S
MIC90
S. aureus
2518
100
0.12
509
100
0.25
S. agalactiae
527
100
0.12
83
100
0.06
Enterococcus spp.
746
99.5
0.12
193
100
0.25
A. baumannii
412
na*
1
115
na
2
Enterobacter spp.
1030
96.6
1
222
94.1
2
E. coli
790
99.9
0.25
332
100
0.5
K. pneumoniae
527
95.1
1
191
92.7
2
*na = not applicable for
this species
Conclusion:
Based on %S and MIC90 data TGC exhibited potent activity against isolates
from all organism groups from complicated skin and soft tissue infections,
regardless of the geographic source. However, given the potential many of
these organisms have for developing resistance, continued and careful
surveillance monitoring is warranted.
Douglas Biedenbach, MS1, Martha Renteria, MD1, Heidi Leister-Tebbe, BSN2 and Dan Sahm, PhD1, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)Pfizer, Inc., Collegeville, PA
Disclosures:
D. Biedenbach,
IHMA, Inc.:
Independent Contractor
,
Research support
M. Renteria,
IHMA, Inc.:
Independent Contractor
,
Research support
H. Leister-Tebbe,
Pfizer, Inc.:
Employee
,
Salary
D. Sahm,
IHMA, Inc.:
Independent Contractor
,
Research support
Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.
Session: Poster Abstract Session: Antibacterial Susceptibility Surveillance